Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer Rowan T. ChlebowskiKathy PanNananda F. Col Review 26 October 2016 Pages: 185 - 190
Contribution of BRCA1 large genomic rearrangements to early-onset and familial breast/ovarian cancer in Pakistan Muhammad U. RashidNoor MuhammadUte Hamann Preclinical study 08 November 2016 Pages: 191 - 201
Using machine learning to parse breast pathology reports Adam YalaRegina BarzilayKevin S. Hughes Preclinical Study 08 November 2016 Pages: 203 - 211
The presence and impact of estrogen metabolism on the biology of triple-negative breast cancer Keely May McNamaraSaki OguroHironobu Sasano Preclinical study 15 November 2016 Pages: 213 - 227
Downregulation of estrogen receptor and modulation of growth of breast cancer cell lines mediated by paracrine stromal cell signals J. HuangP. WoodsR. A. Steinman Preclinical study 16 November 2016 Pages: 229 - 243
Clinical outcomes linked to expression of gene subsets for protein hormones and their cognate receptors from LCM-procured breast carcinoma cells Michael W. DanielsGuy N. BrockJames L. Wittliff Preclinical study 17 November 2016 Pages: 245 - 258
Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis Ruo-Xi WangSheng ChenZhi-Ming Shao Preclinical study 24 November 2016 Pages: 259 - 267
Endocan as a prognostic biomarker of triple-negative breast cancer Atsunobu SagaraKatsuhide IgarashiYoshinori Kato Preclinical study Open access 25 November 2016 Pages: 269 - 278
Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer Xiaoxian LiJing YangJane L. Meisel Preclinical study 25 November 2016 Pages: 279 - 287
Effective treatment of intractable cutaneous metastases of breast cancer with electrochemotherapy: Ten-year audit of single centre experience Mike G. BourkeSlav P. SalwaDeclan M. Soden Clinical trial 22 November 2016 Pages: 289 - 297
Fatigue reduction diet in breast cancer survivors: a pilot randomized clinical trial Suzanna Maria ZickJustin ColacinoZora Djuric Clinical Trial 02 December 2016 Pages: 299 - 310
Up to one-third of breast cancer cases in post-menopausal Mediterranean women might be avoided by modifying lifestyle habits: the EPIC Italy study Giovanna MasalaBenedetta BendinelliDomenico Palli Epidemiology 10 November 2016 Pages: 311 - 320
Pre-diagnostic breastfeeding, adiposity, and mortality among parous Hispanic and non-Hispanic white women with invasive breast cancer: the Breast Cancer Health Disparities Study Avonne E. ConnorKala VisvanathanMartha L. Slattery Epidemiology 11 November 2016 Pages: 321 - 331
Previous GWAS hits in relation to young-onset breast cancer Min ShiKatie M. O’BrienClarice R. Weinberg Epidemiology 15 November 2016 Pages: 333 - 344
Trends in cardiac mortality in women with ductal carcinoma in situ Waqar HaqueVivek VermaBin S. Teh Epidemiology 17 November 2016 Pages: 345 - 351
Differences in mammographic density between Asian and Caucasian populations: a comparative analysis Nadia RajaramShivaani MariapunSoo Hwang Teo Epidemiology 18 November 2016 Pages: 353 - 362
Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511) Rachel A. FreedmanD. K. SeislerH. B. Muss Epidemiology 19 November 2016 Pages: 363 - 373
Discordance between original and central laboratories in ER and HER2 results in a diverse, population-based sample Jennifer J. GriggsAnn S. HamiltonSteven J. Katz Epidemiology 29 November 2016 Pages: 375 - 384
First-line all-oral NORCAP (vinorelbine/capecitabine) might be alternative to taxane-based chemotherapy for HER2-negative metastatic breast cancer Kadri Altundag Letter to the Editor 17 November 2016 Pages: 385 - 385
Erratum to: Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women Lotte E. ElshofMichael SchaapveldJelle Wesseling Erratum 23 November 2016 Pages: 389 - 390
